Research Progress and Challenges in Targeting GLUT1 in Tumors
Open Access
- 17 October 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9225
Abstract
The solute carrier family 2 member 1 (SLC2A1), which encodes glucose transporter 1 (GLUT1), has long been recognized as a key driver of aerobic glycolysis in cancer. However, accumulating evidence has substantially expanded this view, revealing that GLUT1 functions not only as a critical mediator of metabolic reprogramming but also as an important regulator linking tumor metabolism to immune evasion. Notably, GLUT1 expression, regulation, and functional dependence are highly context-dependent across tumor types, disease states, and cellular compartments. Recent studies further link GLUT1-dependent glycolytic flux to immune regulation through glucose competition, lactate accumulation, and metabolite-dependent epigenetic programs within the tumor microenvironment. Reflecting this evolving understanding, therapeutic strategies targeting GLUT1 have progressed from simple metabolic inhibition to approaches that exploit tumor-specific metabolic dependencies and extend to regulated cell death, combination therapy, precision delivery, and selective modulation of malignant and non-malignant cellular compartments. These advances support a shift from expression-centered targeting toward strategies guided by functional GLUT1 dependence and cellular context, while recognizing the metabolic and physiological constraints that shape the therapeutic window. In this review, we systematically summarize recent advances in GLUT1 expression heterogeneity, multilayered regulatory networks, metabolic–immune crosstalk, diagnostic and prognostic relevance, and therapeutic targeting, and discuss how these insights may refine biomarker development, patient selection, and the clinical translation of GLUT1-directed precision metabolic therapy.Keywords
Funding Information
- Natural Science Foundation of Hubei Province (2025AFD782)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0519903)
This publication has 129 references indexed in Scilit:
- Cancer‐Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT‐ANGPTL4 AxisAdvanced Science, 2026
- Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to ChemotherapyAdvanced Materials, 2024
- Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 BlockadeAdvanced Science, 2024
- Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study groupEpilepsia Open, 2020
- Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR‐378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter‐1 (GLUT1) and glycolysisJournal of Cellular Physiology, 2019
- Promotion of Calcium/Calmodulin‐Dependent Protein Kinase 4 by GLUT1‐Dependent Glycolysis in Systemic Lupus ErythematosusArthritis & Rheumatology, 2018
- Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876ChemMedChem, 2016
- Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumorInternational Journal of Cancer, 2011
- Erratum: Chandan VS, Faquin WC, Wilbur DC, et al. The utility of GLUT-1 immunolocalization in cell blocks : An adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck. Cancer (Cancer Cytopathol). 2006; 108(2):124-8.Cancer, 2006
- Glut‐1 deficiency syndrome: Clinical, genetic, and therapeutic aspectsAnnals of Neurology, 2004